18th week of 2022 patent applcation highlights part 30 |
Patent application number | Title | Published |
20220135630 | SMART SINGLE-DOMAIN INTRABODIES WITH PRECISION SWITCHES FOR BIOMEDICAL APPLICATIONS - The present disclosure provides intrabody compositions comprising i) an intrabody and ii) one or more inserts. The disclosure also provides methods for activating and deactivating intracellular and extracellular interactions utilizing the compositions, for instance via chemical and/or light. | 2022-05-05 |
20220135631 | SECRETORY PROTEIN - The disclosure of the present application relates to a secretory deleted split hand/split foot 1 (sDSS1) protein, the amino acid sequence thereof, the nucleic acid sequence thereof, and the applications of the same. The sDSS1 protein is a secretory protein from higher primate, and can be detected in human serum and cerebral spinal fluid (CSF). The sDSS1 protein can form conjugate with oxidized protein under nonenzymatic condition or with amyloid-beta (Aβ) polypeptide to reduce formation of Aβ oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidized protein, Aβ oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly. The protein can be used to prevent and treat the diseases induced by oxidized protein, glycated protein, Aβ protein accumulation, amylin protein accumulation or excessive formation or accumulation of other pathogenic proteins with similar features, and has important potential in biological medicine. | 2022-05-05 |
20220135632 | ALPHA-SYNUCLEIN SUBSTRATES AND METHODS FOR MAKING AND USING THE SAME - An expression vector is provided for production of human alpha-synuclein (αS) protein or a conservative variant thereof that exhibits a decreased tendency to self-aggregate in an αS seed amplification assay (SAA). The expression vector comprises a nucleic acid sequence coding for human αS protein or a conservative variant, the nucleic acid sequence comprising codons that have been optimized to produce human αS protein or a conservative variant when expressed by a host cell such as | 2022-05-05 |
20220135633 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS - The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest. | 2022-05-05 |
20220135634 | PDLIM2 AS A BIOMARKER FOR CANCER AND AS AN ANTI-CANCER TREATMENT TARGET - The present disclosure provides methods and compositions for treating cancer (e.g., lung cancer) in a subject by increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2) in the subject, or a functional fragment thereof. The present disclosure further provides methods of using PDLIM2 as a marker for determining and monitoring a subject's responsiveness to an anti-cancer treatment, providing a prognosis about a cancer in a subject, and selecting an effective anti-cancer treatment for a subject. The present disclosure also provides in vitro methods of screening anti-cancer agents by assessing whether the expression of PDLIM2 is restored by an anti-cancer agent in a cancer cell. | 2022-05-05 |
20220135635 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-05-05 |
20220135636 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-05-05 |
20220135637 | INHIBITION OF MYOSTATIN SIGNAL BY MYOSTATIN SPLICE VARIANT-DERIVED PROTEIN AND UTILIZATION THEREOF - A method of inhibiting myostatin signaling via a myostatin splice variant-derived protein is provided. The protein and an expression system thereof are applicable to therapy for diseases in which myostatin is involved. | 2022-05-05 |
20220135638 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF - The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P | 2022-05-05 |
20220135639 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST - The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof. | 2022-05-05 |
20220135640 | CORTISTATIN OR AN ANALOGUE THEREOF AS A PHARMACEUTICALLY ACTIVE AGENT IN LATENT FORM - The blood half-life of endogenous peptides such as somatostatin and cortistatin is extremely short, barely reaching a few In minutes [Skamene et al., Clin. Endocrinol. 1984, 20, 555-564]. Thus, there is a need to find new systems or compositions that comprise cortistatinor an analogue thereof for the treatment of those pathologies in which specific cortistatin receptors and those receptors shared with other molecules like somatostatin (sstr1, sstr2, sstr3, sstr4 and/or sstr5) and/or ghrelin (GHSR) are expressed, being, furthermore, more stable in blood than cortistatin. The present invention providesan improved means for providing cortistatinor an analogue thereof as a pharmaceutically active agent in latent form, more stable in blood than cortistatin that liberates cortistatin in a controlled-release manner. | 2022-05-05 |
20220135641 | HIGH THROUGHPUT CLONING OF PAIRED BIPARTITE IMMUNORECEPTOR POLYNUCLEOTIDES AND APPLICATIONS THEREOF - Provided herein are compositions and methods for high throughout cloning of fused bipartite immunoreceptor polynucleotides encoding cognate pairs of bipartite immunoreceptors. Also provided herein are various applications of the fused bipartite immunoreceptor polynucleotides, expression vectors containing the fused bipartite immunoreceptor polynucleotides, or cells containing the fused bipartite immunoreceptor polynucleotides or expression vectors. | 2022-05-05 |
20220135642 | CELLS, COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE FUNCTION - The present disclosure relates generally to polypeptides, cells, compositions and methods for enhancing immune function, and in particular the immune function of T cells, such as CD8+ T cells. More particularly, the present invention relates to modified DNAM-1 polypeptides, T cells expressing recombinant and/or modified DNAM-1, and methods of using these cells in adoptive T cell transfer, such as for the treatment of cancer or infection. The disclosure also relates to methods for preparing T cells with enhanced immune function; methods for preparing T cells for adoptive cell therapy; methods for assessing the immune function of T cells in a subject or cell population; methods for predicting the responsiveness of a subject with cancer to cancer therapy; and methods for predicting the survival or survival time of a subject with cancer. | 2022-05-05 |
20220135643 | SOLUBLE THY-1 COMPOSITIONS AND USE THEREOF TO TREAT OR REVERSE FIBROSIS - The invention relates to a soluble Thy-1 polypeptide or a functional fragment thereof and pharmaceutical compositions including the soluble Thy-1 polypeptide or a functional fragment thereof. The invention also relates to the use of the soluble Thy-1 polypeptide or a functional fragment thereof for delivery to subjects with tissue fibrosis for treating, inhibiting, and/or reversing tissue fibrosis in the subject. | 2022-05-05 |
20220135644 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof - The present disclosure provides antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides comprising one or more chemical conjugation sites for incorporation of, for example, epitope containing polypeptides. The present disclosure provides nucleic acids comprising nucleotide sequences encoding antigen-presenting polypeptides comprising one or more chemical conjugation sites, as well as cells genetically modified with the nucleic acids. The single-chain and multimeric antigen-presenting polypeptides and their epitope conjugates are useful for modulating the activity of a T-cell, and accordingly, the present disclosure provides methods of modulating activity of a T-cell in vitro and in vivo as a method of treatment. | 2022-05-05 |
20220135645 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof - The present disclosure provides antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides comprising one or more chemical conjugation sites for incorporation of, for example, epitope containing polypeptides. The single-chain and multi-chain antigen-presenting polypeptides and their epitope conjugates are useful for modulating the activity of a T-cell, and accordingly, the present disclosure provides methods of modulating activity of a T-cell in vitro and in vivo as methods of treatment. | 2022-05-05 |
20220135646 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-05-05 |
20220135647 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-05-05 |
20220135648 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-05-05 |
20220135649 | DOMINANT NEGATIVE CD40L POLYPEPTIDES - Provided herein are dominant negative CD40L polypeptides, as well as compositions comprising the polypeptides and nucleic acids encoding the polypeptides. Methods for inhibiting CD40/CD40L signaling, inhibiting cell proliferation, and preventing and treating conditions such as inflammatory and immune disorders are also provided herein. | 2022-05-05 |
20220135650 | ENGINEERED CD47 EXTRACELLULAR DOMAIN FOR BIOCONJUGATION - Compositions and methods are provided relating to engineered CD47 extracellular domain (ECD) proteins. | 2022-05-05 |
20220135651 | A MEMBRANE-BOUND FIT-1 DECOY AND USES THEREOF - We describe a Flt-1 decoy comprising a VEGF binding domain of Flt-1 and a membrane anchoring domain, in which the Flt-1 decoy does not substantially comprise an intracellular domain. | 2022-05-05 |
20220135652 | ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR - A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein. | 2022-05-05 |
20220135653 | Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections - A topical intranasal antiviral composition for protecting against virus infections. The composition comprises an antigen binder and a pharmaceutical suspender material to allow effective delivery into the nasal cavity. Examples of materials that could be used in the pharmaceutical suspender are microcrystalline cellulose or sodium carboxymethylcellulose (Na⋅CMC). One particular target for the antigen binder could be SARS-CoV-2. For example, the antigen binder could target the S1 subunit of SARS-CoV-2. The composition could be made by a process in which the pharmaceutical vehicle is prepared, and then the antigen binder is added to the pharmaceutical vehicle to make a bioactive mixture, and then adding solid sodium chloride to the bioactive mixture. Also disclosed are methods of protection against virus infection using the intranasal antiviral composition. For example, in the case of SARS-CoV-2, the antigen binder would block the virus particles from attaching to ACE2 receptors on host cells of the nasal mucosa or nasopharynx. This blocking action would protect against virus infection. | 2022-05-05 |
20220135654 | Single Domain Antibodies to SARS-CoV-2 Nucleocapsid Protein - A number of single domain antibodies (sdAb, also known as nanobodies or VHH) were developed that bind nucleocapsid protein of the SARS-CoV-2 virus. They are useful for detecting the virus and could also find application in therapeutics. | 2022-05-05 |
20220135655 | IMMUNOGENETIC RESTRICTION ON ELICITATION OF ANTIBODIES - The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection. | 2022-05-05 |
20220135656 | Anti-Gliadin Antibodies - The present invention provides anti-gliadin antibodies and antibody fragments, and polypeptides encoding the antibodies or fragment. Also disclosed are methods and Kits for the use of such antibodies, fragments, or polypeptides in detection of gliadin. Further provided are heavy chain and light chain variable sequences and associated sequences of complementarity-determining regions (CDRs). | 2022-05-05 |
20220135657 | IMMUNOGLOBULIN VARIABLE DOMAINS - VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I). | 2022-05-05 |
20220135658 | ANTIBODIES TARGETING C5AR - The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer. | 2022-05-05 |
20220135659 | TREATMENT OF NEONATAL HYPOXIA INCLUDING IMPAIRMENTS OR EFFECTS THEREOF - The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated white matter injury, including PVL, in an infant. | 2022-05-05 |
20220135660 | FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region - The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses. | 2022-05-05 |
20220135661 | Monoclonal Antibodies Against Alpha-Synuclein Fibrils - The present disclosure provides monoclonal antibodies that bind α-Synuclein. In certain aspects, the antibodies preferentially bind to α-Synuclein fibrils over α-Synuclein monomer. In other aspects, the invention comprises a method of treating α-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting α-Synuclein fibrils using any of the antibodies of the invention. | 2022-05-05 |
20220135662 | NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1 - The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed. | 2022-05-05 |
20220135663 | Method of treatment of Chronic Low Back Pain - The present invention relates to the treatment of chronic low back pain with an anti-nerve growth factor (NGF) antibody. | 2022-05-05 |
20220135664 | Use of an antibody and antisense in the treatment of Congenital Muscular Dystrophy - The present invention relates to a pharmaceutical composition comprising an antibody that binds to BMP | 2022-05-05 |
20220135665 | Humanized anti-VEGF antibody Fab fragment and use thereof - The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV). | 2022-05-05 |
20220135666 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR - This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a S1P modulator. | 2022-05-05 |
20220135667 | THERAPEUTIC COMBINATIONS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (II) - The present invention relates to pharmaceutical combinations of at least one TNF inhibitor and riboflavin to treat patients suffering from inflammatory bowel disease (IBD) or other inflammatory conditions (such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, lupus erythematous and multiple sclerosis). This invention also relates to additive and/or combinations of at least one TNF inhibitor and riboflavin. This invention is also related to a method for the treatment or prophylaxis of IBD, which method comprises administering a therapeutically effective amount of TNF inhibitor and riboflavin. | 2022-05-05 |
20220135668 | Methods for Treating Psoriasis Using an Anti-IL-23 Antibody - The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis. | 2022-05-05 |
20220135669 | suPAR and Prediction and Treatment of Acute Kidney Injury - Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level. | 2022-05-05 |
20220135670 | ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF - The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease. | 2022-05-05 |
20220135671 | ANTI-SIRP ALPHA ANTIBODIES - The present invention relates to anti-SIRPα antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. | 2022-05-05 |
20220135672 | ANTI-RABBIT CD19 ANTIBODIES AND METHODS OF USE - Herein is reported an antibody binding to rabbit CD19 comprising (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 32 or 33 or 34, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35 or 36, (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 37, (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 38, (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 39, and (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 40, as well as methods of using the same, especially in the identification and selection of antibody producing rabbit B-cells. | 2022-05-05 |
20220135673 | METHODS AND COMPOSITIONS FOR TREATING MAST CELL GASTRITIS, MAST CELL ESOPHAGITIS, MAST CELL ENTERITIS, MAST CELL DUODENITIS, AND/OR MAST CELL GASTROENTERITIS - The present disclosure provides methods for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis. In particular, the present disclosure provides methods for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis. | 2022-05-05 |
20220135674 | CD47 Antibodies and Uses Thereof for Treating Cancer - Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided. | 2022-05-05 |
20220135675 | ANTI-TIM-3 ANTIBODIES AND USE THEREOF - Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions. | 2022-05-05 |
20220135676 | MULTISPECIFIC ANTIGEN BINDING PROTEINS - Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease. | 2022-05-05 |
20220135677 | ANTI-SIRP ALPHA ANTIBODIES - The present invention relates to anti-SIRPα antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. | 2022-05-05 |
20220135678 | METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES - Described herein are novel compositions and methods to improve the safety and efficacy of adoptive cellular therapies of cancer, infection, allergic, degenerative and immune disorders. The disclosure provides a) novel methods and compositions to reduce the accidental insertion of chimeric receptors into cancer cells; b) novel methods to measure the titer of viral vectors; c) novel compositions to generate antigen masking receptors and methods to use such receptors to protect normal cells from immunotherapeutic agents; d) novel compositions and methods to extend the life-span of allogeneic cells, including allogeneic CAR-T cells; e) novel compositions and methods to ameliorate the side-effects of cellular therapies and f) novel compositions of Synthetic Immune Receptors and Ab-TCRs with mutant TCRα constant chains. | 2022-05-05 |
20220135679 | BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO GPNMB AND CD3, AND USE THEREOF - A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB. | 2022-05-05 |
20220135680 | ANTIBODIES BINDING TO HUMAN CD3 AT ACIDIC pH - The invention relates to new anti-hCD3 antibodies that, in contrast to prior art anti-CD3 antibodies, bind specifically to human CD3 at acidic pH, but do not significantly bind to human CD3 at neutral or physiological pH, methods to produce these antibodies and therapeutic uses of these antibodies. These antibodies are able to activate T cells at acidic pH while having significantly reduced activity at neutral or physiological pH. | 2022-05-05 |
20220135681 | Antibodies to Programmed Cell Death Protein 1 - Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation. Immune cells that express PD-1, include but are not limited to B and T cells as well as myeloid-derived cells. In one embodiment, the immune cell is a T cell, preferably a CD8+ T cell. | 2022-05-05 |
20220135682 | Anti-ICOS Antibodies for the Treatment of Cancer - Methods of treating cancer with multiple doses of anti-ICOS antibodies and multiple doses of anti-CTLA4 antibodies are provided. | 2022-05-05 |
20220135683 | ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES - Anti-CTLA4 antibodies, anti-PD1 antibodies, mixtures thereof, polynucleotides encoding such antibodies or mixtures, optionally carried on vectors, and methods of treatment utilizing such antibodies, mixtures, polynucleotides, or vectors are described herein. The anti-CTLA4 and anti-PD1 antibodies have particular sequences and properties. The methods of treatment include uses in treatment of cancer, infections, and immunodeficiency disorders. | 2022-05-05 |
20220135684 | BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28 - Provided herein are novel αPD-L1 antibodies and methods of using such antibodies for the treatment of cancers. In some embodiments, the antibodies are αPD-L1×αCD28 bispecific antibodies. Such antibodies enhance anti-tumor activity by providing a costimulatory signal for T-cell activation against tumor cells while advantageously also blocking inhibitory PD-L1:PD-1 pathway interactions. | 2022-05-05 |
20220135685 | TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY - The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration. | 2022-05-05 |
20220135686 | ANTIBODY THAT BINDS TO HUMAN PD-L1 - Provided are an antibody that binds to human PD-L1, and a tetravalent bispecific antibody against PD-1 and PD-L1 constructed based on the antibody that binds to human PD-L1. The tetravalent bispecific antibody requires no Fc modification, has no mismatch problems, and the preparation method thereof is simple. The biological activities and physical and chemical properties of the tetravalent bispecific antibody are similar with or even better than those of the monoclonal antibodies. | 2022-05-05 |
20220135687 | ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1 - The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof. | 2022-05-05 |
20220135688 | FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE - A fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (T | 2022-05-05 |
20220135689 | ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES - Provided herein are antibodies that selectively bind to HLA-G and and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods. | 2022-05-05 |
20220135690 | METHODS AND COMPOSITIONS RELATING TO CHEMOKINE RECEPTOR VARIANTS - Provided herein are methods and compositions relating to chemokine receptor libraries having nucleic acids encoding for immunoglobulins that bind to chemokine receptors. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein. | 2022-05-05 |
20220135691 | TREATMENT OR PREVENTION METHOD OF RADIATION DAMAGE BY ADMINISTRATION OF IL-5 RECEPTOR ALPHA CHAIN BINDING ANTIBODY - A therapeutic or prophylactic agent for radiation damage associated with radiation exposure, comprising an eosinophil-removing agent as an active ingredient and the like are provided as a technique for efficiently treating or preventing radiation damage associated with radiation exposure. According to the therapeutic or prophylactic agent comprising an eosinophil-removing agent according to the present invention, by suppressing migration and/or infiltration into target tissue and/or proliferation in the tissue of eosinophils and/or inhibiting the activity or function of the eosinophils, pathological conditions such as inflammatory responses and fibrosis of tissue can be suppressed to effectively treat or prevent radiation damage. Moreover, effective radiation therapy can be performed by suppressing radiation damage. | 2022-05-05 |
20220135692 | CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT - The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor. | 2022-05-05 |
20220135693 | Humanized anti-CCR7 receptor antibodies - The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies. | 2022-05-05 |
20220135694 | NOVEL CD40-BINDING ANTIBODIES - The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment. | 2022-05-05 |
20220135695 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS - Methods and systems for desensitizing a human leukocyte antigen (HLA) sensitized subject to prepare for an organ transplant with an improved transplant survival and function, and/or treating or reducing the likelihood of antibody mediated rejection (ABMR) of an organ transplant in a subject are provided, generally including administering an effective amount of an anti-CD38 antibody or a CD38-targeting therapy to reduce the symptoms or ABMR or HLA levels. The subject in the methods may have developed or is experience drug-resistant sensitization, and to whom standard techniques like intravenous immunoglobulin and plasmapheresis are ineffective. | 2022-05-05 |
20220135696 | USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA - The present disclosure provides methods for treating multiple myeloma that comprise administering isatuximab to the individual at a dose of 10 mg/kg on Days 1, 8, 15, and 22 of a first 28-day cycle; administering the isatuximab at a dose of 10 mg/kg on Days 1 and 15 of a 28-day cycle, e.g., for at least 11 cycles, or e.g., until the individual achieves or is determined to achieve at least Very Good Partial Response (VGPR) to treatment; and administering the isatuximab at a dose of 10 mg/kg once every 28 days of one or more additional 28-day cycles. | 2022-05-05 |
20220135697 | CD38 ANTIBODY - The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer. | 2022-05-05 |
20220135698 | J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE - In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided. | 2022-05-05 |
20220135699 | CHIMERIC ANTIGEN RECEPTOR COMPRISING INTERLEUKIN-15 INTRACELLULAR DOMAIN AND USES THEREOF - Provided herein are chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., CD19, CD30, GD2, etc.), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, 4-1BB, etc.). In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods. | 2022-05-05 |
20220135700 | Bispecific HER2 Ligands for Cancer Therapy - The invention relates to a bispecific HER2-targeting agent that includes (a) a first polypeptide ligand that binds to HER2 extracellular domain 1, (b) a second polypeptide ligand that binds to HER2 extracellular domain 4, and (c) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand. | 2022-05-05 |
20220135701 | ANTI-MERTK ANTIBODIES AND THEIR METHODS OF USE - The present disclosure provides anti-MerTK antibodies and methods of use thereof. The methods comprise administering an anti-MerTK antibody or an immunoconjugate thereof. | 2022-05-05 |
20220135702 | NEUROPILIN ANTIBODY NASAL SPRAY TO REDUCE COVID-19 TRANSMISSION - An embodiment provides a method for preventing the transmission of Covid-19, including: preparing a composition comprising an ACE2 monoclonal antibody, a Neuropilin-1 antibody, an antibody to the spike protein of Sars-CoV-2, a vegetable oil, and a saline solution; and spraying the composition in a nasal cavity of a patient. Other aspects are described and claimed. | 2022-05-05 |
20220135703 | METHOD FOR TREATING A DEGENERATIVE NEUROLOGICAL DISORDERS COMPRISING ADMINISTERING ASM INHIBITOR - The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor as an active ingredient. | 2022-05-05 |
20220135704 | ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES - The disclosure provides for single chain variable fragments to MAA-oxidized specific epitopes (OSEs). The disclosure also provides single chain variable fragments that bind to MDA-OSEs or MAA-OSEs on oxidized phospholipids and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents. | 2022-05-05 |
20220135705 | METHOD FOR SUPPORTING THIOL GROUP-INCLUDING COMPOUND - The objective of the present invention is to provide a method for efficiently supporting a thiol group-including compound on an insoluble base material. The method for supporting a thiol group-including compound on an insoluble base material according to the present invention is characterized in comprising Step A: treating the thiol group-including compound with a thiol group-including organic reducing agent and an inorganic reducing agent, and Step B: contacting a reaction liquid of said Step A with the insoluble base material. | 2022-05-05 |
20220135706 | CELLULOSE ACETATE FILM AND METHOD FOR PRODUCING CELLULOSE ACETATE FILM - An object of the present disclosure is to provide a cellulose acetate film having excellent bending properties and high transparency. The subject cellulose acetate film contains cellulose acetate having a cellulose triacetate I crystal structure, the cellulose acetate film having a light transmittance of 70% or higher at 660 nm. | 2022-05-05 |
20220135707 | PROCESSING METHOD OF NATURAL RUBBER LATEX USING CREAMING - A processing method of natural rubber latex using creaming includes the following steps: adding a surfactant, a pH adjuster, and deionized water to natural rubber latex, adding a preservative and a creaming agent, mixing and standing a resulting mixture until phase separation occurs, and collecting an upper rubber latex phase and a lower skim latex phase, separately; diluting the upper rubber latex phase with deionized water, adding a preservative, a pH adjuster, a surfactant, and a creaming agent, mixing and standing a resulting mixture until phase separation occurs, and collecting an obtained upper rubber latex phase; and adding a preservative, a pH adjuster, a surfactant, and a creaming agent to an obtained lower skim latex phase, mixing and standing a resulting mixture until phase separation occurs, and collecting an obtained upper rubber latex phase. | 2022-05-05 |
20220135708 | Aqueous Titanation of Cr/Silica Catalysts by the Use of Acetylacetonate and Another Ligand - A method comprising contacting a silica support with a titanium-containing solution to form a titanated silica support, wherein the titanium-containing solution comprises a solvent; a ligand comprising a glycol, a carboxylate, a peroxide, or a combination thereof, and a titanium compound having the formula Ti(acac) | 2022-05-05 |
20220135709 | METALLACYCLOPENTADIENE INITIATORS FOR CYCLIC POLYMER SYNTHESIS FROM ALKYNES - Provided herein are complexes for polymerization of linear alkynes to cyclic poly(alkynes), and methods of making and using same. For example, provided herein are compounds of formula (I) or formula (IV): | 2022-05-05 |
20220135710 | Catalyst Pretreatment and Feeding System for Polypropylene Production - A process and system for pre-polymerizing propylene are disclosed. A first catalyst suspension is formed by mixing catalyst particles with a hydrocarbon that is a saturated hydrocarbon or propylene. Various other catalyst components are added to the first catalyst suspension, and the first catalyst suspension is then pre-polymerized under pre-polymerization conditions to form a pre-polymerized catalyst suspension that is introduced to a polymerization reactor or a storage tank. The saturated hydrocarbon can be propane, mixed butanes, or mixture thereof. | 2022-05-05 |
20220135711 | DIELECTRIC ELASTOMERIC MATERIAL - A dielectric elastomeric material having a permittivity of 20-65 at 10 | 2022-05-05 |
20220135712 | Polyethylene Having High Pressure Resistance and Crosslinked Polyethylene Pipe Comprising the Same - The present disclosure relates to a polyethylene having high pressure resistance and a crosslinked polyethylene pipe including the same. The polyethylene according to the present disclosure has high melt index and density and exhibits a sufficient degree of crosslinking, thereby exhibiting excellent strength and pressure resistance characteristics. | 2022-05-05 |
20220135713 | HIGHLY BRANCHED, LOW MOLECULAR WEIGHT POLYOLEFINS AND METHODS FOR THEIR PRODUCTION - Low molecular weight, highly branched polyolefins are provided. Also provided are catalyst-mediated methods of making the low molecular weight, highly branched polyolefins and a catalyst system for carrying out the methods. The catalyst system is a homogeneous catalytic system that includes a single-site organozirconium complex and hydrocarbon-soluble perfluoroarylborate co-catalyst that is highly active for the oligomerization of olefin monomers in non-polar media. | 2022-05-05 |
20220135714 | NUCLEATED PROPYLENE POLYMER COMPOSITION WITH HIGH TOUGHNESS - The present invention is directed to a propylene polymer composition comprising (a) at least 90 wt. %, based on the weight of the total propylene homopolymer composition, of a propylene homopolymer having (i) a pentad isotacticity (mmmm) of equal or more than 98.0 mol.-%, determined by quantitative | 2022-05-05 |
20220135715 | Polypropylene Resin, Polypropylene Fiber And Method For Preparing The Same - The present disclosure relates to a polypropylene resin exhibiting excellent processability and capable of producing fine fibers, a polypropylene fiber including the same, and a method for preparing the same. | 2022-05-05 |
20220135716 | THERMOPLASTIC PARTICULATES COATED WITH POLYMER NANOPARTICLES AND METHODS FOR PRODUCTION AND USE THEREOF - Additive manufacturing processes featuring consolidation of thermoplastic particulates may form printed objects in a range of shapes. Inorganic nanoparticles disposed upon the outer surface of the thermoplastic particulates may improve flow performance of the thermoplastic particulates during additive manufacturing, but may be undesirable to incorporate in some printed objects. Polymer nanoparticles may be substituted for inorganic nanoparticles in some instances to address this difficulty and provide other advantages. Particulate compositions suitable for additive manufacturing may comprise: a plurality of thermoplastic particulates comprising a thermoplastic polymer and a plurality of polymer nanoparticles disposed upon an outer surface of the thermoplastic particulates, the polymer nanoparticles comprising a crosslinked fluorinated polymer. | 2022-05-05 |
20220135717 | CONTINUOUS SYNTHESIS OF AN ETHYLENE AND BUTADIENE COPOLYMER - A process for the synthesis of an ethylene/butadiene copolymer is provided. The process is continuous and comprises the following steps:
| 2022-05-05 |
20220135718 | MULTI-COMPONENT IONOMER - A multi-component ionomer, wherein, in a multi-component copolymer (D) comprising, as essential constitutional units, a structural unit (A) derived from at least one selected from the group consisting of ethylene and an α-olefin containing 3 to 20 carbon atoms, a structural unit (B) derived from a monomer containing at least one selected from the group consisting of a carboxy group and a dicarboxylic anhydride group, and a structural unit (C) derived from a specific acyclic monomer, at least a part of at least one selected from the group consisting of a carboxy group and a dicarboxylic anhydride group of the structural unit (B) is converted into a specific metal-containing carboxylate, and wherein a phase angle δ at which an absolute value G* of a complex modulus measured with a rotational rheometer is 0.1 MPa (G*=0.1 MPa) is from 50 degrees to 75 degrees. | 2022-05-05 |
20220135719 | POLYMERS OF HALOALKYL AND HALOALKENYL ETHER (METH)ACRYLATES - A curable composition containing at least one of a haloalkyl ether (meth)acrylate or a haloalkenyl ether (meth)acrylate and, optionally, one or more different types of co-monomers is cured to provide a polymer having advantageous properties as a result of the incorporation of halogenated functionality derived from the haloalkyl/haloalkenyl ether (meth)acrylate monomer. | 2022-05-05 |
20220135720 | COMPOSITIONS WITH HIGH REFRACTIVE INDEX AND ABBE NUMBER - Disclosed are co-polymers which are produced from reactive monomer mixtures and which have both high refractive index and a high Abbe number. These materials are well suited for use as implantable ophthalmic devices and have a refractive index which may be edited through application of energy. When used for an intraocular lens, the high refractive index allows for a thin lens which compresses to allow a small incision size. | 2022-05-05 |
20220135721 | FABRICATION OF SOLID MATERIALS OR FILMS FROM A POLYMERIZABLE LIQUID - The disclosure describes a polymerizable liquid that includes a reactive oligomer and a reactive monomer. The polymerizable liquid is an energy polymerizable liquid hardenable by a single reaction mechanism forming a Photoplastic material. The disclosure further describes a method of producing the Photoplastic material and articles that can be made from the Photoplastic material. | 2022-05-05 |
20220135722 | CONJUGATED POLYELECTROLYTE-GRAFTED MEMBRANE AND METHOD FOR MANUFACTURING THE SAME - The present disclosure relates to a conjugated polyelectrolyte-grafted membrane, which is obtained by fixing a conjugated polyelectrolyte (CPE) capable of generating active oxygen under visible light irradiation to a membrane through crosslinking, and can remove contaminants in water, while reducing bio-fouling on the surface of the membrane, by generating active oxygen through a photocatalytic reaction of the conjugated polyelectrolyte (CPE), as well as to a method for manufacturing the same. The method for manufacturing a conjugated polyelectrolyte-grafted membrane includes the steps of: preparing a conjugated polyelectrolyte (CPE); coating a conjugated polyelectrolyte (CPE) on the surface of a membrane; and carrying out crosslinking of the conjugated polyelectrolyte (CPE) with the surface of the membrane. | 2022-05-05 |
20220135723 | GRAFT COPOLYMER AND USE THEREOF - The present invention provides a polyvinyl alcohol graft copolymer including a polyvinyl alcohol main chain. The polyvinyl alcohol graft copolymer includes branched chains including structural units derived from the following monomers: (a) a fluorine-including ethylenically unsaturated monomer, (b) an ethylenically unsaturated carboxylic acid monomer, and (c) an ethylenically unsaturated amide monomer. The present invention also provides an aqueous binder composition, and an electrode slurry composition including the polyvinyl alcohol graft copolymer. | 2022-05-05 |
20220135724 | ADHESIVE FILM AND OPTICAL DEVICE INCLUDING THE SAME - An adhesive film includes an upper protective layer, a lower protective layer, and an adhesive layer between the upper protective layer and the lower protective layer. The adhesive layer includes a first adhesive layer and a second adhesive layer on the first adhesive layer. The first adhesive layer includes an acrylic resin, a photoinitiator, and a monofunctional monomer. The second adhesive layer includes an acrylic resin, a photoinitiator, and a multifunctional monomer. | 2022-05-05 |
20220135725 | METHOD FOR PRODUCING DIENE-BASED GRAFT COPOLYMER RESIN AND DIENE-BASED GRAFT COPOLYMER RESIN - The present invention relates to a method for producing a diene-based graft copolymer resin, and a diene-based graft copolymer resin produced therefrom, the method including: mixing an aromatic vinyl-based monomer, a diene-based rubber polymer, and a polymerization initiator to prepare a first reactant; mixing a vinyl cyan-based monomer and an antioxidant to prepare a second reactant; adding and polymerizing the first reactant and the second reactant into a polymerization reactor to prepare a polymer; and removing unreacted monomers in a devolatilization tank. | 2022-05-05 |
20220135726 | CROSS-LINKED POLYMER FOR RESIST - A cross-linked polymer including a structure wherein at least a portion of phenolic hydroxyl groups in the polymer is protected by a group represented by the following formula (1): | 2022-05-05 |
20220135727 | DISPERSANTS MADE FROM ISOCYANATES AND AMINES - The present disclosure generally relates to a dispersant obtained from the reaction of a liquid isocyanate compound and a polyoxyalkylene amine and its use in dispersing various particulate solids in an aqueous or organic medium. | 2022-05-05 |
20220135728 | ADHESIVE AND FLEXIBLE DISPLAY USING THE SAME - Provided is an adhesive provided by patterning a metal plate with a predetermined elastic modulus, wherein the adhesive is compressively deformed in response to an operation of an adherend to be folded, so that the adhesive can easily return to an original state thereof through formation of a plurality of inner neutral planes upon deformation. | 2022-05-05 |
20220135729 | POLYCARBONATE DIOLS - A polycarbonate diol containing a repeating unit represented by the specific formula (A) and a terminal hydroxyl group, wherein more than 0 mol % and not more than 3.0 mol % of the terminals thereof is an oxolane terminal represented by the specific formula (B). | 2022-05-05 |